# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-22-000038
Filing Date
2022-04-22
Accepted
2022-04-22 16:11:27
Documents
11
Period of Report
2022-06-10

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ligand-2022annualmeetingpr.htm | DEF 14A | 1211923
2 |  | a2021psuchart.jpg | GRAPHIC | 27594
3 |  | image.jpg | GRAPHIC | 192798
4 |  | image1.jpg | GRAPHIC | 76162
5 |  | image2.jpg | GRAPHIC | 274329
6 |  | image_0.jpg | GRAPHIC | 12141
7 |  | image_2.jpg | GRAPHIC | 268584
8 |  | partneredpipeline_updated.jpg | GRAPHIC | 315201
9 |  | picture1.jpg | GRAPHIC | 106020
10 |  | picture2.jpg | GRAPHIC | 105834
11 |  | stockgraph.jpg | GRAPHIC | 142646
| Complete submission text file | 0000886163-22-000038.txt |  | 3284680

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 22845613
SIC: 2834 Pharmaceutical Preparations